162 related articles for article (PubMed ID: 25003574)
1. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.
Fujiwara S; Hung M; Yamamoto-Ibusuk CM; Yamamoto Y; Yamamoto S; Tomiguchi M; Takeshita T; Hayashi M; Sueta A; Iwase H
Oncotarget; 2014 Jun; 5(11):3919-30. PubMed ID: 25003574
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.
Machleidt A; Buchholz S; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
BMC Cancer; 2013 Sep; 13():437. PubMed ID: 24063248
[TBL] [Abstract][Full Text] [Related]
3. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.
Thor AD; Edgerton SM; Jones FE
Am J Pathol; 2009 Nov; 175(5):1802-9. PubMed ID: 19808643
[TBL] [Abstract][Full Text] [Related]
4. HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen.
Göthlin Eremo A; Tina E; Wegman P; Stål O; Fransén K; Fornander T; Wingren S
Int J Oncol; 2015 Oct; 47(4):1311-20. PubMed ID: 26238412
[TBL] [Abstract][Full Text] [Related]
5. HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation.
Han W; Jones FE
Biochem Biophys Res Commun; 2014 Jan; 443(2):458-63. PubMed ID: 24333426
[TBL] [Abstract][Full Text] [Related]
6. "Shedding" light on HER4 signaling in normal and malignant breast tissues.
Brockhoff G
Cell Signal; 2022 Sep; 97():110401. PubMed ID: 35820544
[TBL] [Abstract][Full Text] [Related]
7. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
[TBL] [Abstract][Full Text] [Related]
10. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer.
Ko E; Park SE; Cho EY; Kim Y; Hwang JA; Lee YS; Nam SJ; Bang S; Park J; Kim DH
Breast Cancer Res; 2010; 12(6):R100. PubMed ID: 21092257
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.
Wali VB; Gilmore-Hebert M; Mamillapalli R; Haskins JW; Kurppa KJ; Elenius K; Booth CJ; Stern DF
Breast Cancer Res; 2014 Dec; 16(6):501. PubMed ID: 25516216
[TBL] [Abstract][Full Text] [Related]
12. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.
Zhu Y; Sullivan LL; Nair SS; Williams CC; Pandey AK; Marrero L; Vadlamudi RK; Jones FE
Cancer Res; 2006 Aug; 66(16):7991-8. PubMed ID: 16912174
[TBL] [Abstract][Full Text] [Related]
13. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.
Jones FE
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):247-58. PubMed ID: 18473151
[TBL] [Abstract][Full Text] [Related]
14. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
[TBL] [Abstract][Full Text] [Related]
15. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.
Mohd Nafi SN; Generali D; Kramer-Marek G; Gijsen M; Strina C; Cappelletti M; Andreis D; Haider S; Li JL; Bridges E; Capala J; Ioannis R; Harris AL; Kong A
Oncotarget; 2014 Aug; 5(15):5934-49. PubMed ID: 25153719
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic HER4/4ICD transcriptional activation domains are required for STAT5A activated gene expression.
Han W; Sfondouris ME; Semmes EC; Meyer AM; Jones FE
Gene; 2016 Oct; 592(1):221-226. PubMed ID: 27502417
[TBL] [Abstract][Full Text] [Related]
17. HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
Wege AK; Chittka D; Buchholz S; Klinkhammer-Schalke M; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
Breast Cancer Res; 2018 Nov; 20(1):139. PubMed ID: 30458882
[TBL] [Abstract][Full Text] [Related]
18. The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor α is not expressed.
Munk M; Memon A; Poulsen SS; Borre M; Nexo E; Sorensen BS
Scand J Clin Lab Invest; 2013 Sep; 73(6):503-13. PubMed ID: 24015958
[TBL] [Abstract][Full Text] [Related]
19. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
20. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
Naresh A; Thor AD; Edgerton SM; Torkko KC; Kumar R; Jones FE
Cancer Res; 2008 Aug; 68(15):6387-95. PubMed ID: 18676864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
